BACKGROUND: Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. METHODS: The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricemia was defined as UA ≥500 μmoL/L and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricemia, with treated hyperuricemia, and with untreated hyperuricemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricemia, unlike those with hyperuricemia, had a higher left ventricular ejection fraction, a better renal function, and higher hemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. RESULTS: In a primary analysis, the patients without hyperuricemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricemia had a similar 5-year survival rate as those with untreated hyperuricemia (42.0% vs 39.7%, P = 0.362) whereas those with treated hyperuricemia had a poorer prognosis (32.4% survival rate, P = 0.006 vs non-hyperuricemia group and P = 0.073 vs untreated group). CONCLUSION: Hyperuricemia was associated with an unfavorable cardiovascular risk profile in HF patients. Treatment with low doses of allopurinol did not improve the prognosis of HF patients.

1st Department of Internal Medicine Cardiology and Angiology St Anne's University Hospital Brno Brno Czech Republic

2nd Department of Internal Medicine Department of Cardiology and Angiology 1st Faculty of Medicine of the Charles University Prague and General University Hospital Prague Czech Republic

Department of Cardiology Hospital Na Homolce Prague Czech Republic

Department of Cardiology Institute of Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiology Tomas Bata Regional Hospital Zlin Czech Republic

Department of Internal Medicine and Cardiology University Hospital Brno Brno Czech Republic Department of Internal Medicine Military Hospital Brno Brno Czech Republic

Department of Internal Medicine and Cardiology University Hospital Brno Brno Czech Republic Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hospital Frydek Mistek Frydek Mistek Czech Republic

Department of Internal Medicine Hospital Havlickuv Brod Havlickuv Brod Czech Republic

Department of Internal Medicine Hospital Znojmo Znojmo Czech Republic

Department of Internal Medicine University Hospital Olomouc Olomouc Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic 1st Department of Internal Medicine Cardiology and Angiology St Anne's University Hospital Brno Brno Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic 2nd Department of Internal Medicine St Anne's University Hospital Brno Brno Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

University Hospital Kralovske Vinohrady and the 3rd Faculty of Medicine of the Charles University Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc20006341

003      

CZ-PrNML

005      

20200527111309.0

007      

ta

008      

200511s2019 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1002/clc.23197 $2 doi

035    __

$a (PubMed)31119751

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Pavlusova, Marie $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.

245    10

$a Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry / $c M. Pavlusova, J. Jarkovsky, K. Benesova, J. Vitovec, A. Linhart, P. Widimsky, L. Spinarova, K. Zeman, J. Belohlavek, F. Malek, M. Felsoci, J. Kettner, P. Ostadal, C. Cihalik, J. Spac, H. Al-Hiti, M. Fedorco, R. Fojt, A. Kruger, J. Malek, T. Mikusova, Z. Monhart, S. Bohacova, L. Pohludkova, F. Rohac, J. Vaclavik, D. Vondrakova, K. Vyskocilova, M. Bambuch, G. Dostalova, S. Havranek, I. Svobodová, L. Dusek, J. Spinar, R. Miklik, J. Parenica,

520    9_

$a BACKGROUND: Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. METHODS: The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricemia was defined as UA ≥500 μmoL/L and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricemia, with treated hyperuricemia, and with untreated hyperuricemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricemia, unlike those with hyperuricemia, had a higher left ventricular ejection fraction, a better renal function, and higher hemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. RESULTS: In a primary analysis, the patients without hyperuricemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricemia had a similar 5-year survival rate as those with untreated hyperuricemia (42.0% vs 39.7%, P = 0.362) whereas those with treated hyperuricemia had a poorer prognosis (32.4% survival rate, P = 0.006 vs non-hyperuricemia group and P = 0.073 vs untreated group). CONCLUSION: Hyperuricemia was associated with an unfavorable cardiovascular risk profile in HF patients. Treatment with low doses of allopurinol did not improve the prognosis of HF patients.

650    _2

$a akutní nemoc $7 D000208

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a alopurinol $x aplikace a dávkování $7 D000493

650    _2

$a biologické markery $x krev $7 D015415

650    _2

$a příčina smrti $7 D002423

650    _2

$a vztah mezi dávkou a účinkem léčiva $7 D004305

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    _2

$a antiuratika $x aplikace a dávkování $7 D006074

650    _2

$a srdeční selhání $x komplikace $x mortalita $7 D006333

650    _2

$a lidé $7 D006801

650    _2

$a hyperurikemie $x krev $x komplikace $x farmakoterapie $7 D033461

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a prognóza $7 D011379

650    12

$a tendenční skóre $7 D057216

650    _2

$a prospektivní studie $7 D011446

650    12

$a registrace $7 D012042

650    _2

$a míra přežití $x trendy $7 D015996

650    _2

$a časové faktory $7 D013997

650    _2

$a výsledek terapie $7 D016896

650    _2

$a kyselina močová $x krev $7 D014527

651    _2

$a Česká republika $x epidemiologie $7 D018153

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

700    1_

$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

700    1_

$a Benesova, Klara $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

700    1_

$a Vitovec, Jiri $u Faculty of Medicine, Masaryk University, Brno, Czech Republic. First Department of Internal Medicine, Cardiology and Angiology, St Anne's University Hospital Brno, Brno, Czech Republic.

700    1_

$a Linhart, Ales $u Second Department of Internal Medicine, Department of Cardiology and Angiology, First Faculty of Medicine of the Charles University, Prague, and General University Hospital in Prague, Czech Republic.

700    1_

$a Widimsky, Petr $u University Hospital Kralovske Vinohrady and the Third Faculty of Medicine of the Charles University, Prague, Czech Republic.

700    1_

$a Spinarova, Lenka $u Faculty of Medicine, Masaryk University, Brno, Czech Republic. First Department of Internal Medicine, Cardiology and Angiology, St Anne's University Hospital Brno, Brno, Czech Republic.

700    1_

$a Zeman, Kamil $u Department of Internal Medicine, Hospital Frydek-Mistek, Frydek-Mistek, Czech Republic.

700    1_

$a Belohlavek, Jan $u Second Department of Internal Medicine, Department of Cardiology and Angiology, First Faculty of Medicine of the Charles University, Prague, and General University Hospital in Prague, Czech Republic.

700    1_

$a Malek, Filip $u Department of Cardiology, Hospital Na Homolce, Prague, Czech Republic.

700    1_

$a Felsoci, Marian $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.

700    1_

$a Kettner, Jiri $u Department of Cardiology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.

700    1_

$a Ostadal, Petr $u Department of Cardiology, Hospital Na Homolce, Prague, Czech Republic.

700    1_

$a Cihalik, Cestmir $u Department of Internal Medicine, University Hospital Olomouc, Olomouc, Czech Republic.

700    1_

$a Spac, Jiri $u Faculty of Medicine, Masaryk University, Brno, Czech Republic. Second Department of Internal Medicine, St Anne's University Hospital Brno, Brno, Czech Republic.

700    1_

$a Al-Hiti, Hikmet $u Department of Cardiology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.

700    1_

$a Fedorco, Marian $u Department of Internal Medicine, University Hospital Olomouc, Olomouc, Czech Republic.

700    1_

$a Fojt, Richard $u University Hospital Kralovske Vinohrady and the Third Faculty of Medicine of the Charles University, Prague, Czech Republic.

700    1_

$a Kruger, Andreas $u Department of Cardiology, Hospital Na Homolce, Prague, Czech Republic.

700    1_

$a Malek, Josef $u Department of Internal Medicine, Hospital Havlickuv Brod, Havlickuv Brod, Czech Republic.

700    1_

$a Mikusova, Tereza $u First Department of Internal Medicine, Cardiology and Angiology, St Anne's University Hospital Brno, Brno, Czech Republic.

700    1_

$a Monhart, Zdenek $u Department of Internal Medicine, Hospital Znojmo, Znojmo, Czech Republic.

700    1_

$a Bohacova, Stanislava $u Department of Cardiology, Tomas Bata Regional Hospital, Zlin, Czech Republic.

700    1_

$a Pohludkova, Lidka $u Department of Internal Medicine, Hospital Frydek-Mistek, Frydek-Mistek, Czech Republic.

700    1_

$a Rohac, Filip $u University Hospital Kralovske Vinohrady and the Third Faculty of Medicine of the Charles University, Prague, Czech Republic.

700    1_

$a Vaclavik, Jan $u Department of Internal Medicine, University Hospital Olomouc, Olomouc, Czech Republic.

700    1_

$a Vondrakova, Dagmar $u Department of Cardiology, Hospital Na Homolce, Prague, Czech Republic.

700    1_

$a Vyskocilova, Klaudia $u First Department of Internal Medicine, Cardiology and Angiology, St Anne's University Hospital Brno, Brno, Czech Republic.

700    1_

$a Bambuch, Miroslav $u Department of Cardiology, Tomas Bata Regional Hospital, Zlin, Czech Republic.

700    1_

$a Dostalova, Gabriela $u Second Department of Internal Medicine, Department of Cardiology and Angiology, First Faculty of Medicine of the Charles University, Prague, and General University Hospital in Prague, Czech Republic.

700    1_

$a Havranek, Stepan $u Second Department of Internal Medicine, Department of Cardiology and Angiology, First Faculty of Medicine of the Charles University, Prague, and General University Hospital in Prague, Czech Republic.

700    1_

$a Svobodová, Ivana $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

700    1_

$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

700    1_

$a Spinar, Jindrich $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.

700    1_

$a Miklik, Roman $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine, Military Hospital Brno, Brno, Czech Republic.

700    1_

$a Parenica, Jiri $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.

773    0_

$w MED00001122 $t Clinical cardiology $x 1932-8737 $g Roč. 42, č. 8 (2019), s. 720-727

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31119751 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20200511 $b ABA008

991    __

$a 20200527111306 $b ABA008

999    __

$a ok $b bmc $g 1525199 $s 1096397

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 42 $c 8 $d 720-727 $e 20190529 $i 1932-8737 $m Clinical cardiology $n Clin Cardiol $x MED00001122

GRA    __

$a MUNI/A/1250/2017 $p Masaryk University, Brno

GRA    __

$a 65269705 $p Ministry of Health of the Czech Republic

LZP    __

$a Pubmed-20200511